Downregulation of serum miR-106b: a potential biomarker for Alzheimer disease

References

• Alzheimer’s Association. 2018. 2018 Alzheimer’s disease facts and figures. Alzheimer’s & dementia, 14 (3), 367–429.
   Web of Science ®Google Scholar
• Bateman, R.J., et al., 2006. Quantifying CNS protein production and clearance rates in humans using in vivo stable isotope labeling, immunoprecipitation, and tandem mass spectrometry. Nature medicine, 12 (7), 856–861.
   PubMed Web of Science ®Google Scholar
• Chen, X., et al., 2008. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell research, 18 (10), 997–1006.
   PubMed Web of Science ®Google Scholar
• Cheng, L., et al., 2015. Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment. Molecular psychiatry, 20 (10), 1188–1196.
   PubMed Web of Science ®Google Scholar
• Fang, J.H., et al., 2011. MicroRNA‐29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression. Hepatology, 54 (5), 1729–1740.
   PubMed Web of Science ®Google Scholar
• Guo, R., et al., 2017. A 9-microRNA signature in serum serves as a noninvasive biomarker in early diagnosis of Alzheimer’s disease. Journal of Alzheimer’s disease, 60 (4), 1365–1377.
   PubMed Web of Science ®Google Scholar
• He, L., and Hannon, G.J., 2004. MicroRNAs: small RNAs with a big role in gene regulation. Nature reviews genetics, 5 (7), 522–531.
   PubMed Web of Science ®Google Scholar
• Iwata, N., et al., 2000. Identification of the major Aβ 1–42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nature medicine, 6 (2), 143–150.
   PubMed Web of Science ®Google Scholar
• Kim, J., et al., 2009. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular Aβ clearance. Neuron, 64 (5), 632–644.
   PubMed Web of Science ®Google Scholar
• Kim, J., et al., 2012. MiR-106b impairs cholesterol efflux and increases Aβ levels by repressing ABCA1 expression. Experimental neurology, 235 (2), 476–483.
   PubMed Web of Science ®Google Scholar
• Korkmaz, G., et al., 2012. miR-376b controls starvation and mTOR inhibition-related autophagy by targeting ATG4C and BECN1. Autophagy, 8 (2), 165–176.
   PubMed Web of Science ®Google Scholar
• Kumar, S., and Reddy, P.H., 2018. MicroRNA-455-3p as a potential biomarker for Alzheimer’s disease: An update. Frontiers in aging neuroscience, 10, 41.
   PubMed Web of Science ®Google Scholar
• Li, L., et al., 2013. Autophagy enhancer carbamazepine alleviates memory deficits and cerebral amyloid-β pathology in a mouse model of Alzheimer’s disease. Current Alzheimer research, 10 (4), 433–441.
   PubMed Web of Science ®Google Scholar
• Liang, B., et al., 2017. MicroRNA-20a/b regulates cholesterol efflux through post-transcriptional repression of ATP-binding cassette transporter A1. Biochimica et Biophysica Acta (Bba) - molecular and cell biology of lipids, 1862 (9), 929–938.
   PubMed Web of Science ®Google Scholar
• Liu, W., Zhao, J., and Lu, G., 2016. miR-106b inhibits tau phosphorylation at Tyr18 by targeting Fyn in a model of Alzheimer’s disease. Biochemical and biophysical research communications, 478 (2), 852–857.
   PubMed Web of Science ®Google Scholar
• Livak, K.J., and Schmittgen, T.D., 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods, 25 (4), 402–408.
   PubMed Web of Science ®Google Scholar
• Luo, Z-l., et al., 2016. Negative correlation of ITCH E3 ubiquitin ligase and miRNA-106b dictates metastatic progression in pancreatic cancer. Oncotarget, 7 (2), 1477.
   PubMedGoogle Scholar
• Madadi, S., and Soleimani, M., 2019. Study of serum microrna expression in an amyotrophic lateral sclerosis patient: challenge of selecting suitable internal control for normalization. Muscle & nerve, 59 (1), E2–E3.
   PubMed Web of Science ®Google Scholar
• Madadi, S., et al., 2019. MicroRNA expression studies: challenge of selecting reliable reference controls for data normalization. Cellular and molecular life sciences, 76, 3497–3514.
   PubMed Web of Science ®Google Scholar
• Mawuenyega, K.G., et al., 2010. Decreased clearance of CNS β-amyloid in Alzheimer’s disease. Science, 330 (6012), 1774–1774.
   PubMed Web of Science ®Google Scholar
• Mitchell, P.S., et al., 2008. Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the national academy of sciences, 105 (30), 10513–10518.
   PubMed Web of Science ®Google Scholar
• Ni, X., et al., 2014. Downregulation of miR‐106b induced breast cancer cell invasion and motility in association with overexpression of matrix metalloproteinase 2. Cancer science, 105 (1), 18–25.
   PubMed Web of Science ®Google Scholar
• Riancho, J., et al., 2017. MicroRNA profile in patients with Alzheimer’s disease: analysis of miR-9-5p and miR-598 in raw and exosome enriched cerebrospinal fluid samples. Journal of Alzheimer’s disease, 57 (2), 483–491.
   PubMed Web of Science ®Google Scholar
• Ryan, N.S., and Rossor, M.N., 2010. Correlating familial Alzheimer’s disease gene mutations with clinical phenotype. Biomarkers in medicine, 4 (1), 99–112.
   PubMed Web of Science ®Google Scholar
• Salon, M.L., et al., 2003. Relationship between β-amyloid degradation and the 26S proteasome in neural cells. Experimental neurology, 180 (2), 131–143.
   PubMed Web of Science ®Google Scholar
• Schwarzenbach, H., et al., 2014. Clinical relevance of circulating cell-free microRNAs in cancer. Nature reviews clinical oncology, 11 (3), 145–156.
   PubMed Web of Science ®Google Scholar
• Waller, R., et al., 2017. Serum miRNAs miR-206, 143-3p and 374b-5p as potential biomarkers for amyotrophic lateral sclerosis (ALS). Neurobiology of aging, 55, 123–131.
   PubMed Web of Science ®Google Scholar
• Wan, Y., et al., 2015. Identification of differential microRNAs in cerebrospinal fluid and serum of patients with major depressive disorder. PloS one, 10 (3), e0121975.
   PubMed Web of Science ®Google Scholar
• Wang, C., et al., 2015. A panel of five serum miRNAs as a potential diagnostic tool for early-stage renal cell carcinoma. Scientific reports, 5 (1), 7610.
   PubMedGoogle Scholar
• Wang, H., et al., 2010. miR-106b aberrantly expressed in a double transgenic mouse model for Alzheimer’s disease targets TGF-β type II receptor. Brain research, 1357, 166–174.
   PubMed Web of Science ®Google Scholar
• Weller, R.O., et al., 2000. Cerebral amyloid angiopathy: accumulation of Aβ in interstitial fluid drainage pathways in Alzheimer’s disease. Annals of the New York academy of sciences, 903 (1 VASCULAR FACT), 110–117.
   PubMedGoogle Scholar
• Wiedrick, J.T., et al., 2019. Validation of MicroRNA Biomarkers for Alzheimer’s Disease in Human Cerebrospinal Fluid. Journal of Alzheimer’s disease, 67, 875–891
   PubMed Web of Science ®Google Scholar
• Wildsmith, K.R., et al., 2013. Evidence for impaired amyloid β clearance in Alzheimer’s disease. Alzheimer’s research & therapy, 5 (4), 33.
   PubMed Web of Science ®Google Scholar
• Zhai, Z., et al., 2013. miR-106b fine tunes ATG16L1 expression and autophagic activity in intestinal epithelial HCT116 cells. Inflammatory bowel diseases, 19 (11), 2295–2301.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., et al., 2016. Serum miRNAs panel (miR-16-2*, miR-195, miR-2861, miR-497) as novel non-invasive biomarkers for detection of cervical cancer. Scientific reports, 5 (1), 17942.
   Web of Science ®Google Scholar
• Zhao, Z.-B., et al., 2014. MicroRNA-922 promotes tau phosphorylation by downregulating ubiquitin carboxy-terminal hydrolase L1 (UCHL1) expression in the pathogenesis of Alzheimer’s disease. Neuroscience, 275, 232–237.
   PubMed Web of Science ®Google Scholar